Gainers

• MaxCyte (NASDAQ:MXCT) stock increased by 21.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $130.0 million.
• Vir Biotechnology (NASDAQ:VIR) shares moved upwards by 19.16% to $14.55. The market value of their outstanding shares is at $1.9 billion. As per the press release, Q3 earnings came out 3 days ago.
• Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 18.69% to $2.54. The market value of their outstanding shares is at $20.6 million.
• Heron Therapeutics (NASDAQ:HRTX) shares moved upwards by 18.32% to $0.35. The company's market cap stands at $55.6 million. As per the press release, Q3 earnings came out today.
• Lakewood-Amedex (NASDAQ:LABT) shares increased by 13.66% to $0.44.
• PharmaCyte Biotech (NASDAQ:PMCB) stock increased by 13.61% to $0.41. The market value of their outstanding shares is at $3.8 million.

Losers

• Zura Bio (NASDAQ:ZURA) shares declined by 74.3% to $1.05 during Monday's pre-market session. The market value of their outstanding shares is at $393.9 million.
• Faeth Therapeutics (NASDAQ:FTH) stock fell 22.45% to $17.1. The company's market cap stands at $568.4 million. The company's, Q3 earnings came out 4 days ago.
• Intelligent Bio Solutions (NASDAQ:INBS) stock fell 15.23% to $1.67. The market value of their outstanding shares is at $6.5 million.
• Karyopharm Therapeutics (NASDAQ:KPTI) shares declined by 14.76% to $0.05. The market value of their outstanding shares is at $1.2 million.
• Bullfrog AI Hldgs (NASDAQ:BFRG) stock fell 12.94% to $0.45. The market value of their outstanding shares is at $9.6 million.
• CytoMed Therapeutics (NASDAQ:GDTC) shares decreased by 12.69% to $0.75. The company's market cap stands at $10.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.